Q2 2024 EPS Estimates for Poseida Therapeutics, Inc. (NASDAQ:PSTX) Cut by Analyst

Poseida Therapeutics, Inc. (NASDAQ:PSTX - Free Report) - Equities research analysts at William Blair reduced their Q2 2024 earnings per share (EPS) estimates for shares of Poseida Therapeutics in a report issued on Wednesday, May 15th. William Blair analyst S. Corwin now forecasts that the company will post earnings per share of ($0.38) for the quarter, down from their prior forecast of ($0.36). The consensus estimate for Poseida Therapeutics' current full-year earnings is ($1.77) per share. William Blair also issued estimates for Poseida Therapeutics' Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.18) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.05) EPS and FY2025 earnings at ($1.27) EPS.

Poseida Therapeutics (NASDAQ:PSTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.09. The business had revenue of $25.00 million during the quarter, compared to analyst estimates of $12.50 million. Poseida Therapeutics had a negative return on equity of 97.36% and a negative net margin of 131.95%.

Separately, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Poseida Therapeutics in a research note on Thursday, May 2nd.

Poseida Therapeutics Stock Down 4.6 %

Poseida Therapeutics stock traded down $0.16 during mid-day trading on Friday, hitting $3.19. The company had a trading volume of 520,312 shares, compared to its average volume of 699,839. The company has a market capitalization of $309.30 million, a PE ratio of -2.65 and a beta of 0.46. The stock's 50 day moving average price is $2.82 and its two-hundred day moving average price is $2.99. Poseida Therapeutics has a 12 month low of $1.54 and a 12 month high of $4.27. The company has a current ratio of 2.56, a quick ratio of 3.18 and a debt-to-equity ratio of 0.69.

Hedge Funds Weigh In On Poseida Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC purchased a new position in shares of Poseida Therapeutics during the third quarter valued at approximately $29,000. Bayesian Capital Management LP bought a new position in shares of Poseida Therapeutics during the 1st quarter valued at $33,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Poseida Therapeutics in the 4th quarter worth $36,000. Tower Research Capital LLC TRC boosted its stake in shares of Poseida Therapeutics by 110.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company's stock worth $36,000 after buying an additional 5,606 shares during the last quarter. Finally, Keystone Financial Group bought a new stake in shares of Poseida Therapeutics in the third quarter worth $36,000. Institutional investors own 46.87% of the company's stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.